Literature DB >> 21467942

Clinical parameters including serum pepsinogen level and management strategy in patients with premalignant gastric dysplasia.

Young Woon Chang1, Young Hwangbo, Jae Won Lee, Sook Jung Jo, Jun Hyung Cho, Jaejun Shim, Jae Young Jang, Hyo Jong Kim, Byung Ho Kim.   

Abstract

OBJECTIVE: Surgical or endoscopic resection is recommended for the management of gastric high-grade dysplasia (HGD). However, there are no proper guidelines for the management of gastric low-grade dysplasia (LGD). We evaluated clinical parameters, histological results, and endoscopic follow-up to find a management strategy of LGD.
METHODS: A total of 590 patients with LGD, HGD, functional dyspepsia (FD), and early or advanced gastric cancer (EGC or AGC, respectively) were consecutively enrolled. We examined the association of clinical parameters including low serum pepsinogen (PG) I/II ratio of 3.0 or less with the disease phenotypes. Histological results between initial forceps biopsy and final endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) specimens were compared. Complications and recurrence were evaluated after EMR or ESD.
RESULTS: The PG I/II ratio in FD was 4.2±1.7 (mean±SD), but was significantly lower in LGD (2.8±1.6, P<0.0001). The PG I/II ratio was not any lower in the HGD, EGC, and AGC groups. In patients with FD having a PG I/II ratio of 3.0 or less, multiple logistic regression analysis showed smoking habits and high salt intake were independent risk factors for gastric dysplasia or gastric cancer. About 11% (n=8/70) of LGD lesions were upgraded to HGD (6/70) or EGC (2/70) after EMR or ESD. Neither serious complications nor recurrence at the primary site after EMR or ESD were found in LGD.
CONCLUSION: It is proposed that endoscopic resection followed by endoscopic surveillance might be a beneficial strategy for patients with LGD having a PG I/II ratio of 3.0 or less.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467942     DOI: 10.1097/MEG.0b013e328346105a

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.

Authors:  Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali
Journal:  Biomed Rep       Date:  2017-09-20

2.  How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis.

Authors:  Guangfeng Zhao; Meng Xue; Yingying Hu; Sanchuan Lai; Shujie Chen; Liangjing Wang
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

3.  Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm.

Authors:  Jae Hwang Cha; Jin Seok Jang
Journal:  Korean J Intern Med       Date:  2018-11-07       Impact factor: 2.884

4.  Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.

Authors:  Chang Seok Bang; Jae Jun Lee; Gwang Ho Baik
Journal:  J Clin Med       Date:  2019-05-10       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.